Although not statistically significant, this trend suggests that H/L HCC tumors may exhibit more frequent PI3K signaling activation, potentially influencing treatment responses to PI3K/AKT/mTOR-targeted therapies. This evidence concerns the gene MTOR and hepatocellular carcinoma.